<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">121545</article-id><article-id pub-id-type="doi">10.23868/gc121545</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Some possible molecular mechanisms of VEGF encoding plasmids functioning</article-title><trans-title-group xml:lang="ru"><trans-title>Возможные молекулярные механизмыфункционирования плазмидных конструкций,содержащих ген VEGF</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Grigorian,</surname><given-names>A S</given-names></name><name xml:lang="ru"><surname>Григорян,</surname><given-names>А С</given-names></name></name-alternatives><bio xml:lang="en"><p>Human Stem Cells Institute, Moscow</p></bio><bio xml:lang="ru"><p>ОАО «Институт Стволовых Клеток Человека», Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Schevchenko</surname><given-names>K G</given-names></name><name xml:lang="ru"><surname>Шевченко</surname><given-names>К Г</given-names></name></name-alternatives><bio xml:lang="en"><p>Human Stem Cells Institute, Moscow</p></bio><bio xml:lang="ru"><p>ОАО «Институт Стволовых Клеток Человека», Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Human Stem Cells Institute, Moscow</institution></aff><aff><institution xml:lang="ru">ОАО «Институт Стволовых Клеток Человека», Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2011-09-15" publication-format="electronic"><day>15</day><month>09</month><year>2011</year></pub-date><volume>6</volume><issue>3</issue><issue-title xml:lang="en">NO3 (2011)</issue-title><issue-title xml:lang="ru">№3 (2011)</issue-title><fpage>24</fpage><lpage>28</lpage><history><date date-type="received" iso-8601-date="2023-01-11"><day>11</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2011, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2011, Эко-Вектор</copyright-statement><copyright-year>2011</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/121545">https://genescells.ru/2313-1829/article/view/121545</self-uri><abstract xml:lang="en"><p>Gene therapeutic approaches to the restoration of the
ischemic tissue perfusion are considered very promising,
but to this time the molecular mechanisms which allow the
therapeutic gene encoding plasmid to transfect the target
cell and underlie the positive clinical effects remain unknown.
In this review the possible molecular mechanisms of the
angiogenic factor VEGF encoding plasmid penetration into the
cytoplasm and the nucleus of the target cell are discussed,
and also the methods for better transfection and the gene of
interest expression are proposed.</p></abstract><trans-abstract xml:lang="ru"><p>Гентерапевтические подходы к восстановлению пер-
фузии ишемизированной ткани считаются весьма пер-
спективными, однако до настоящего времени неизвестны
все молекулярные механизмы, позволяющие плазмиде со
встроенным терапевтическим геном проникнуть в клетку-
мишень, и лежащие в основе положительных клинических
эффектов терапии. В данном обзоре обсуждаются возмож-
ные молекулярные механизмы проникновения плазмид-
ных конструкций, несущих ген ангиогенного фактора VEGF
(vascular endothelial growth factor), в цитоплазму и ядро
клетки-мишени, а также предлагаются способы повышения
эффективности трансфекции клеток и экспрессии интере-
сующего гена.</p></trans-abstract></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nature Medicine 2003; 9: 669-76.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Ferraro B., Cruz Y.L., Baldwin M., Coppola D., Heller R. Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation. Gene Therapy 2010; 17: 763-9.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Nikol S. Viral or non-viral angiogenesis gene transfer - New answers to old questions. Cardiovasc. Res. 2007; 73: 443-5.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Sylven C. Angiogenic gene therapy. Drugs of today 2002; 38: 819-27.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Деев Р.В., Григорян А.С., Потапов И.В. и др. Мировой опыт и тенденции генной терапии ишемических заболеваний. Ангиология и сосуд. хирургия 2011; 17 (2): 145-54.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Wiley Gene Therapy Clinical Trials Worldwide. http://www.wiley. com/legacy/wileychi/genmed/clinical/</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Douglas J. Adenoviral vectors for gene therapy. Mol. Biotechnol. 2007; 36 (1): 71-80.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Yang Y., Wilson J.M. Clearance of adenovirus-infected hepatocytes by MHC class I restricted CD4+ CTLs in vivo. J. Immunol. 1995; 155: 2564-9.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Melillo G., Scoccianti M., Kovesdi I. et al. Gene therapy for collateral vessel development. Cardiovasc. Res. 1997; 35: 480-9.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Williams P.D., Ranjzad P., Kakar S.J. Development of viral vectors for use in cardiovascular gene therapy. Viruses 2010; 2: 334-71.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Harris J.D., Lemoine N.R. Strategies for targeted gene therapy. Trends Genet. 1996; 12: 400-5.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Sinn P.L., Sauter S.L., McCray P.B. Lipoplex size is a major determinant of in vitro lipofection efficiency. Gene Therapy 2005; 12: 1089-98.</mixed-citation></ref></ref-list></back></article>
